@Article{,
AUTHOR = {Sender Herschorn},
TITLE = {Cardiovascular safety of PDE5 inhibitors},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {10},
YEAR = {2003},
NUMBER = {Suppl.1},
PAGES = {23--28},
URL = {http://www.techscience.com/CJU/v10nSuppl.1/63396},
ISSN = {1488-5581},
ABSTRACT = {Erectile dysfunction (ED) and cardiovascular disease
share many of the same risk factors and have some
common elements of pathophysiology. Clinically, they
often coexist. Another link between the two conditions
is that sildenafil, the first oral therapeutic agent effective
in treating ED, has been shown to potentiate the
hypotensive effects of nitrates, a potentially serious side
effect. Nitrates are commonly used in the treatment of
coronary artery disease. As such, sildenafil (and, likely,
other new phosphodiesterase type 5 [PDE5] inhibitors)
is contraindicated in men who use nitrate medications.
This article will examine the risk of an acute coronary
event during sexual activity, and review an algorithm
for evaluating the cardiac risk of a patient with ED. The
interaction between PDE5 inhibitors and cardiac
medications will be discussed, along with guidelines for
using sildenafil in men with cardiac disease.},
DOI = {}
}